Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun;9(1):171-194.
doi: 10.1007/s40122-020-00162-8. Epub 2020 Mar 14.

Resolving Issues About Efficacy and Safety of Low-Dose Codeine in Combination Analgesic Drugs: A Systematic Review

Ivan Ćelić  1 , Lidija Bach-Rojecky  2 , Iveta Merćep  3   4 , Ana Soldo  5 , Anja Kos Petrak  6 , Ana Bučan  6
Affiliations
Review

Resolving Issues About Efficacy and Safety of Low-Dose Codeine in Combination Analgesic Drugs: A Systematic Review

Ivan Ćelić et al. Pain Ther. 2020 Jun.

Abstract

Introduction: The objective of this systematic review is to reflect on assumptions in relation to codeine use in combination with other analgesics.

Methods: MEDLINE was searched according to the predetermined keywords and criteria. Only English language studies were taken into consideration and the outcome data of the final studies were extracted by two reviewers independently from each other and were checked by the third reviewer. Additionally, the available codeine-related Individual Case Safety Reports (ICSRs) retrieved from EudraVigilance were reviewed.

Results: Sixteen placebo-controlled studies that involved 3378 subjects suffering from acute pain were analyzed for the efficacy of low-dose codeine (≤ 30 mg) combination products. Twelve of them found low-dose codeine combinations more efficient in relieving pain than the assigned comparator. According to 20 randomized clinical trials which included at least one dose of codeine (from 30 to 240 mg daily), the vast majority of reported side-effects were mild or moderate in severity. A total of 20 ICSRs for dependence were identified in the EudraVigilance database with codeine as a suspect drug for the 10-year time period for the European region.

Conclusions: Low-dose codeine combinations are effective after a single application in treating acute pain. Codeine in doses ≤ 30 mg and higher was considered safe since only mild to moderate side-effects were observed. There is no indication in the available sources which clearly links low doses of codeine to substance use disorder in non-dependent subjects.

Keywords: Acute pain; Clinical studies; Combination analgesic drugs; Efficacy; Low-dose codeine; Review; Safety; Substance-use disorder.

PubMed Disclaimer

Conflict of interest statement

Lidija Bach-Rojecky is a member of the Advisory Board at Alkaloid AD Skopje. Lidija Bach-Rojecky reports personal fees from Alkaloid AD Skopje, PLIVA Hrvatska, Sandoz Hrvatska, and Medis Adria for giving lectures, outside the submitted work. Ivan Ćelić reports speaking fees for the following companies: Alkaloid AD Skopje and Sandoz. Iveta Merćep, Anja Kos Petrak, Ana Soldo and Ana Bučan have nothing to disclose. Anja Kos Petrak is now affiliated with Makpharm Ltd., Pharmacovigilance Department, Zagreb, Croatia.

Figures

Fig. 1
Fig. 1
Search strategy summary for efficacy and safety as per the predetermined inclusion and exclusion criteria
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nielsen S, Van Hout MC. Over-the-counter codeine-from therapeutic use to dependence, and the grey areas in between. Curr Top Behav Neurosci. 2017;34:59–75. doi: 10.1007/7854_2015_422. - DOI - PubMed
    1. Yaksh TL, Wallace MS. Opiods, analgesia, and pain management. In: Brunton LL, Hilal-Dundan R, Knollmann BC, editors. Goodman & Gilman’s: the pharmacological basis of therapeutics. New York: McGraw Hill Education; 2018. pp. 355–385.
    1. Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, Haidar CE, Shen DD, Callaghan JT, Sadhasivam S, Prows CA, Kharasch ED, Skaar TC, Clinical Pharmacogenetics Implementation Consortium Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014;95(4):376–382. doi: 10.1038/clpt.2013.254. - DOI - PMC - PubMed
    1. Sekhri NK, Cooney MF. Opioid metabolism and pharmacogenetics: clinical implications. J Perianesth Nurs. 2017;32(5):497–505. doi: 10.1016/j.jopan.2017.07.005. - DOI - PubMed
    1. Dean L. Codeine therapy and CYP2D6 genotype. In: Pratt V, McLeod H, Dean L, Malheiro A, Rubinstein W (eds) Medical genetics summaries. Bethesda: National Center for Biotechnology Information; 2012. http://www.ncbi.nlm.nih.gov/books/NBK100662/. Acessed 31 May 2019. - PubMed

LinkOut - more resources